Type Specificity and Significance of Different Isotypes of Serum Antibodies to Human Papillomavirus Capsids

Wang, Z. H.; Kjellberg, Lennart; Abdalla, Haydar; Wiklund, Fredrik; Eklund, Carina; Knekt, Paul; Lehtinen, Matti; Kallings, Ingegerd; Lenner, Per; Hallmans, Göran; Mählck, Carl-Gustav; Wadell, Göran; Schiller, John T.; Dillner, Joakim

doi:10.1086/315232

Cited by 48 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A number of studies have supported the use of HPV-16 VLP as a biomarker of past HPV exposure, with moderate associations between HPV seropositivity and cervical cancer Dillner et al, 1996). As previously reported, the magnitude of association between seropositivity and cervical cancer in this study were 2 -3-fold compared to HPV seronegative women Chua et al, 1996;Dillner et al, 1996Dillner et al, , 1997Wideroff et al, 1996;Wang et al, 2000;Sigstad et al, 2002). Our stratified analyses clearly demonstrated that HPV DNApositive women had the highest levels of risk for CIN3/cancer; for HPV-18 and -31, risk for CIN3/cancer was highest for women both HPV DNA-and sero-positive followed by women DNA-positive only.…”

Section: Discussionsupporting

confidence: 79%

Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica

et al. 2003

View full text Add to dashboard Cite

Human papillomavirus (HPV) seroprevalence and determinants of seropositivity were assessed in a 10 049-woman population-based cohort in Guanacaste, Costa Rica. Serologic responses based on VLP-based ELISA were obtained from the plasma collected at study enrollment in 1993/1994 for HPV-16 (n ¼ 9949), HPV-18 (n ¼ 9928), HPV-31 (n ¼ 9932), and HPV-45 (n ¼ 3019). Seropositivity was defined as five standard deviations above the mean optical density obtained for studied virgins (n ¼ 573). 15, 16, and 11%, respectively. Of women DNA-positive for , seropositivity was 45, 34, 51, and 28%, respectively. Peak HPV seroprevalence occurred a decade after DNA prevalence; lifetime number of sexual partners was the key determinant of seropositivity independent of DNA status and age. DNA-and sero-positive women showed the highest risk for concurrent CIN3/cancer, followed by DNA-positive, sero-negative women. British Journal of Cancer (2003) (Ho et al, 1995). The prevalence of HPV DNA therefore underestimates the cumulative incidence of infection in a population, particularly where the majority of women will not develop persistent infection or cervical neoplasia. Measurement of serum antibody to HPV capsids (or virus-like particles (VLPs)) has been demonstrated as a useful although imperfect marker of past and cumulative HPV exposure, thus complementing the assessment of HPV DNA (Kirnbauer et al, 1994;Wideroff et al, 1995Wideroff et al, , 1999Carter et al, 1996;Sasagawa et al, 1998;Touze et al, 2001).As part of a large population-based study of the natural history of HPV infection and cervical neoplasia in Guanacaste, Costa Rica, we report here the population-based seroprevalence in Guanacaste women of four oncogenic HPV types found in the majority of cervical cancers worldwide Munoz et al, 2003). The data presented document the baseline burden of HPV exposure in Guanacaste, Costa Rica. As a major objective, we determined the association of risk for concurrent diagnosis of CIN3/cancer with HPV assessed jointly by serology and PCR-based DNA testing. As only about half of all HPV-DNA-positive women are seropositive using available VLP assays (Kirnbauer et al, 1994;Le Cann et al, 1995), we also investigated determinants of seropositivity in our population. METHODS Study populationThis study was conducted in an on-going population-based cohort study of 10 049 women in Guanacaste, Costa Rica (Herrero et al, 1997;Hildesheim et al, 2001) who were enrolled in 1993 -1994 with the approval of the National Cancer Institute (NCI) and local institutional review boards; all participants provided written informed consent. Briefly, the cohort was a representative sample of the adult population based on selection by cluster sampling, with oversampling for cancer. Participation among eligible women exceeded 90%, and participants completed a risk factor questionnaire that addressed demographic, behavioural, and sexual practices. Women were screened using three cytologic and one visual test at enrollment; colposcopy referral with biopsy was perform...

show abstract

Section: Discussionsupporting

confidence: 79%

Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica

et al. 2003

View full text Add to dashboard Cite

show abstract

“…HPV seropositivity was previously found to be linked with several characteristics, mainly sexual activity indicators such as lifetime number of sexual partners, HSV-2 seropositivity, and marital status, as well as to oral contraceptive use and smoking (5,8,14,17,23,(35)(36)(37)(38)(39)(40). In the present study, a clear dose-response relationship was observed for both HPV16 and HPV18 seropositivity with lifetime number of sexual partners, the most important risk factor for cervical HPV DNA prevalence in the same populations (41).…”

Section: Discussionsupporting

confidence: 64%

Seroprevalence of Antibodies against Human Papillomavirus (HPV) Types 16 and 18 in Four Continents: the International Agency for Research on Cancer HPV Prevalence Surveys

Vaccarella

Franceschi²,

Clifford³

et al. 2010

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Few human papillomavirus (HPV) seroprevalence studies have been carried out in women from low-resource countries.Methods: Seroprevalence of antibodies against HPV16 and HPV18 was assessed in 7,074 women ≥15 years of age (median 44 years) from eight world areas. Serum antibodies against HPV16 and HPV18 were tested for using enzyme-linked immunosorbent assay. HPV DNA was assessed using a general primer GP5 +/6+-mediated PCR.Results: HPV16 and HPV18 seroprevalence both ranged from <1% (Hanoi, Vietnam) to ≥25% (Nigeria). Of women who were HPV16 or HPV18 DNA-positive, seropositivity for the same type was 39.8% and 23.2%, respectively. Seropositivity for either type was directly associated with markers of sexual behavior. HPV16 and/or 18 (HPV16/18)-seropositive women had an increased risk of having cytologic abnormalities only if they were also HPV DNA-positive. A high international correlation was found between HPV16/18 seroprevalence and overall HPV DNA prevalence (r = 0.81; P = 0.022). However, HPV16/18 seroprevalence was substantially higher than the corresponding DNA prevalence in all study areas (although to different extents) and, contrary to DNA, tended to increase from young to middle age, and then decline or remain fairly constant. In all study areas, the vast majority of the information on the burden of exposure to HPV16/18 derived from serology.Conclusions: The correlation between HPV DNA and HPV serology was not very good at an individual woman level, but high at a population level.Impact: HPV serology is a poor marker of current infection or related lesions, but it can contribute, together with DNA, in evaluating the variations in the burden of HPV infection worldwide. Cancer Epidemiol Biomarkers

show abstract

“…HPV seroprevalence doubled to 25% among sexually active women in this study, and this increase was seen independently for each of the seven HPV types tested. Although a strong increase in HPV seropositivity with increasing number of sexual partners has been widely reported (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16), far fewer studies have allowed a comparison with women reporting to be nonsexually active (6,29).…”

Section: Discussionmentioning

confidence: 99%

Serologic Response to Oncogenic Human Papillomavirus Types in Male and Female University Students in Busan, South Korea

Clifford

Shin

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

112

103

View full text Add to dashboard Cite

In the absence of genital samples, human papillomavirus (HPV) serology may be useful to assess HPV infection in young men and women. HPV seroprevalence and determinants of seropositivity were assessed in 817 female and 518 male university students in Busan, South Korea, of whom 74% and 44%, respectively, reported never having had penetrative sexual intercourse. Type-specific HPV DNA status, assessed by a short PCR fragment primer set, was available from genital samples. Seropositivity to L1 proteins of HPV types 16, 18, 31, 33, 45, 52, and 58 were assessed using multiplex HPV serology. Among women, HPV seroprevalence was significantly higher among sexually active (26.1%) than nonsexually active students [11.1%, odds ratio (OR) = 2.9; 95% confidence interval (95% CI), 1.8-4.7], although the association was weaker than that for HPV DNA prevalence (OR, 14; 95% CI, 4.7-42). Furthermore, HPV seroprevalence was higher among HPV DNA-positive (24%) than HPV DNAnegative women (13%), and there was a positive correlation of type-specific seroprevalence with the presence of HPV DNA of the same type. In contrast, HPV seropositivity among men was not associated with sexual behavior or the presence of HPV DNA. Seroprevalence correlates with genital HPV exposure in young women, but its meaning in young men is unclear.

show abstract

Type Specificity and Significance of Different Isotypes of Serum Antibodies to Human Papillomavirus Capsids

Cited by 48 publications

References 30 publications

Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica

Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica

Seroprevalence of Antibodies against Human Papillomavirus (HPV) Types 16 and 18 in Four Continents: the International Agency for Research on Cancer HPV Prevalence Surveys

Serologic Response to Oncogenic Human Papillomavirus Types in Male and Female University Students in Busan, South Korea

Contact Info

Product

Resources

About